Under the terms of the agreement, Getz Pharma will be granted a licence to commercialize HLX03 in Pakistan, the Philippines, Vietnam, Cambodia, Myanmar, Nigeria, Kenya, Sri Lanka, Ukraine, Kazakhstan and Uzbekistan, as well as other territories, where agreed.

Adalimumab is a human monoclonal antibody that treats autoimmune diseases by inhibiting tumour necrosis factor (TNF), a soluble inflammatory cytokine. Adalimumab binds to TNF-alpha (TNF-α), preventing it from activating TNF receptors, which cause the inflammatory reactions associated with autoimmune diseases. Adalimumab is indicated for the treatment of rheumatoid arthritis, juvenile idiopathic and psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, psoriasis, and ulcerative colitis.

HLX03 was approved by China’s National Medical Products Administration (NMPA) in December 2020 for the treatment of rheumatoid arthritis, ankylosing spondylitis and plaque psoriasis in China and is the first product from Henlius to be approved for the treatment of autoimmune diseases [1].

Henlius has three copy biologicals approved in China. The company has also gained NMPA approval for its rituximab biosimilar Hanlikon (HLX01) [2], the first China-developed copy biological following the new guidelines [3], and for its trastuzumab biosimilar Han Quyou (HLX02) [4].

Zercepac (HLX02) was also approved in Europe in July 2020, making it the first China-developed monoclonal antibody biosimilar to be approved in the region [5].

Related article
Biosimilars of adalimumab

References
1. GaBI Online - Generics and Biosimilars Initiative. China approves adalimumab copy biological HLX03 biosimilar from Samsung Bioepis [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Apr 1]. Available from: www.gabionline.net/biosimilars/news/China-approves-adalimumab-copy-biological-HLX03
2. GaBI Online - Generics and Biosimilars Initiative. China approves rituximab copy biological [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Apr 1]. Available from: www.gabionline.net/Biosimilars/News/China-approves-rituximab-copy-biological
3. GaBI Online - Generics and Biosimilars Initiative. Chinese guidelines for copy biologicals [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Apr 1]. Available from: www.gabionline.net/Guidelines/Chinese-guidelines-for-copy-biologicals
4. GaBI Online - Generics and Biosimilars Initiative. Copy biologicals approved in China [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Apr 1]. Available from: www.gabionline.net/biosimilars/general/copy-biologicals-approved-in-china
5. GaBI Online - Generics and Biosimilars Initiative. EC approval for trastuzumab biosimilar Zercepac [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Apr 1]. Available from: www.gabionline.net/Biosimilars/News/EC-approval-for-trastuzumab-biosimilar-Zercepac

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2022 Pro Pharma Communications International. All Rights Reserved.